Owlet Q3 revenue beats estimates on higher product sales

Owlet

13/11/2025 21:28

Overview

Owlet Q3 revenue rises 44.6% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company reports record Q3 net income of $4.1 mln, reversing a loss in Q3 2024

Outlook

Owlet expects full-year 2025 revenue between $103 mln and $106 mln

Company anticipates 2025 gross margins of 48% to 50%

Owlet projects 2025 adjusted EBITDA between $1.25 mln and $2 mln

Result Drivers

PRODUCT SALES - Increased sales of Dream Sock and Dream Duo products drove revenue growth

INTERNATIONAL EXPANSION - Strong international growth with 171% increase yr/yr, supported by new regulatory clearance in India

SUBSCRIPTION GROWTH - Owlet360 subscription surpasses 85,000 paying subscribers, expanding to international markets

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$32 mln
$27.18 mln (4 Analysts)
Q3 Adjusted EPS
Beat
$0.03
-$0.21 (2 Analysts)
Q3 Adjusted EBITDA
Beat
$1.60 mln
$483,250 (4 Analysts)
Q3 Gross Margin
50.60%
Q3 Gross Profit
$16.20 mln
Q3 Operating Expenses
$15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Owlet Inc is $13.00, about 15.4% above its November 12 closing price of $11.00

Press Release: ID:nBw2t1FJ1a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)